PRECIGEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.41 USD | +0.71% |
|
+6.02% | +5.22% |
| 04-24 | Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy | CI |
| 03-25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
| Sales 2024 * | 5.59M 447M | Sales 2025 * | 45.44M 3.64B | Capitalization | 351M 28.1B |
|---|---|---|---|---|---|
| Net income 2024 * | -89M -7.12B | Net income 2025 * | -73M -5.84B | EV / Sales 2024 * | 18.8 x |
| Net cash position 2024 * | 246M 19.69B | Net cash position 2025 * | 157M 12.57B | EV / Sales 2025 * | 4.27 x |
| P/E ratio 2024 * |
-4.19
x | P/E ratio 2025 * |
-6.17
x | Employees | 202 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Precigen, Inc.
More recommendations
More press releases
| 1 day | +0.71% | ||
| 1 week | +6.02% | ||
| Current month | -2.76% | ||
| 1 month | -2.76% | ||
| 3 months | +2.17% | ||
| 6 months | +39.60% | ||
| Current year | +5.22% |
1 week
1.32
1.45
1 month
1.281.49
Current year
1.191.79
1 year
0.841.88
3 years
0.818.72
5 years
0.8111.10
10 years
0.8169.45
| Managers | Title | Age | Since |
|---|---|---|---|
Helen Sabzevari
CEO | Chief Executive Officer | 62 | 31/12/19 |
Harry Thomasian
DFI | Director of Finance/CFO | 62 | 30/09/21 |
Randal Kirk
CHM | Chairman | 70 | 31/01/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Randal Kirk
CHM | Chairman | 70 | 31/01/08 |
Dean Mitchell
BRD | Director/Board Member | 68 | 28/02/09 |
Jeffrey Perez
PRN | Corporate Officer/Principal | 52 | 31/07/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.41 | +0.71% | 413,594 |
| 25/04/24 | 1.4 | -1.41% | 611,778 |
| 24/04/24 | 1.42 | +1.43% | 568,981 |
| 23/04/24 | 1.4 | +1.45% | 507,021 |
| 22/04/24 | 1.38 | +3.76% | 890,547 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Companyâs proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Sector
Pharmaceuticals
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.41
USD
Average target price
9
USD
Spread / Average Target
+538.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.22% | 351M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PGEN Stock
